EGFR and gastric cancer: Based on the mRNA expression levels, TIMP1, DSG2, RRM1, MUC2, EGFR, ZDHHC14, and CLDN18.2 were denoted as the potential biomarker candidates that could predict the pathological response of locally advanced GC to each NAC regimen.